VTP50469
- CAS No.
- 2169916-18-9
- Chemical Name:
- VTP50469
- Synonyms
- VTP50469;VTP50469, 10 mM in DMSO;5-Fluoro-N,N-diisopropyl-2-((4-(7-((trans-4-(methylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)benzamide;Benzamide, 5-fluoro-N,N-bis(1-methylethyl)-2-[[4-[7-[[trans-4-[(methylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-;Menin-MLL,leukemia,survival,VTP 50469,Epigenetic Reader Domain,antiproliferative,Apoptosis,Inhibitor,protein-protein,VTP-50469,inhibit,VTP50469,differentiation
- CBNumber:
- CB75839891
- Molecular Formula:
- C32H47FN6O4S
- Molecular Weight:
- 630.82
- MDL Number:
- MFCD32197139
- MOL File:
- 2169916-18-9.mol
| Boiling point | 735.2±70.0 °C(Predicted) |
|---|---|
| Density | 1.28±0.1 g/cm3(Predicted) |
| solubility |
DMSO: Soluble: =10 mg/ml Ethanol: Sparingly soluble: 1-10 mg/ml |
| form | Solid |
| pka | 10.97±0.40(Predicted) |
| color | White to light yellow |
| InChIKey | ADHHOUXZPBYYSU-YOCNBXQISA-N |
| SMILES | C(N(C(C)C)C(C)C)(=O)C1=CC(F)=CC=C1OC1=CN=CN=C1N1CC2(CCN(C[C@@H]3CC[C@@H](NS(C)(=O)=O)CC3)CC2)C1 |
VTP50469 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0077527 | VTP50469 99.41% | 2169916-18-9 | 5mg | $450 | 2021-12-16 | Buy |
| ChemScene | CS-0077527 | VTP50469 99.41% | 2169916-18-9 | 10mg | $780 | 2021-12-16 | Buy |
| ChemScene | CS-0077527 | VTP50469 99.41% | 2169916-18-9 | 50mg | $2150 | 2021-12-16 | Buy |
| ChemScene | CS-0077527 | VTP50469 99.41% | 2169916-18-9 | 100mg | $2850 | 2021-12-16 | Buy |
| DC Chemicals | 012382 | VTP50469 | 2169916-18-9 | 003 | $3600 | 2021-12-16 | Buy |
VTP50469 Chemical Properties,Uses,Production
Uses
VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity[1][2].
in vivo
VTP50469 (15-60 mg/kg; oral administration; twice a day; for 28 days; NSG mice) treatment is highly efficacious across all dosage levels and all treatment groups have a significant survival advantage. Mice dosed at 30 and 60 mg/kg VTP50469 extends survival advantage[1].
| Animal Model: | Unconditioned immunodeficient (NSG) mice with MV4;11 cells[1] |
| Dosage: | 15 mg/kg, 30 mg/kg, and 60 mg/kg |
| Administration: | Oral administration; twice a day; for 28 days |
| Result: | Was highly efficacious across all dosage levels and all treatment groups had a significant survival advantage over the control group. |
References
[1] Krivtsov AV, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 Dec 9;36(6):660-673.e11. DOI:10.1016/j.ccell.2019.11.001
[2] Andrei V. Krivtsov, et al. Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia. Cancer Resceach. July 2018.Volume 78, Issue 13 Supplement.
VTP50469 Preparation Products And Raw materials
Raw materials
Preparation Products
VTP50469 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32433 | 58 |
| Nantong HI-FUTURE Biology Co., Ltd. | +undefined18051384581 | sales@chemhifuture.com | China | 3135 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39031 | 58 |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | masar@topule.com | China | 8467 | 58 |
| Zibo Hangyu Biotechnology Development Co., Ltd | +86-0533-2185556 +8615965530500 | nickzhang@hangyubiotech.com | China | 10996 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 52924 | 58 | |
| Zhengzhou Haode Pharmaceutical Technology Co.,Ltd | 18037386321 | 3330511471@qq.com | China | 500 | 58 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 | sales-cpd@caerulumpharma.com | China | 3503 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 71826 | 60 |
